News Breaks |
|
|
| February 27, 2013 |
| 13:53 EDT |  | SRPT, GSK | Sarepta higher after report of hospitalizations related to GSK drug
Shares of Sarepta Therapeutics (SRPT) are up $2.86, or 9.85%, to $31.89 and the strength is being attributed to a report by TheStreet.com that said patients were hospitalized after being treated with GlaxoSmithKline's (GSK) experimental drug for Duchenne muscular dystrophy. The report adds that Sarepta is scheduled to meet with the FDA this quarter to discuss a possible accelerated approval filing of its own Duchenne muscular dystrophy treatment, eteplirsen. |
|
|
News For SRPT;GSK From The Last 14 Days Check below for free stories on SRPT;GSK the last two weeks. |
|
|
| June 18, 2013 |
| 08:37 EDT |  | GSK | Drug companies turn to microchips to test medicines, WSJ reports
 Subscribe for More Information |
|
| 07:13 EDT | | GSK | Aspen in talks buy GSK's Arixtra, Fraxiparine brands
Subscribe for More Information |
|
| 07:07 EDT | | GSK | GlaxoSmithKline receives offer for thrombosis brands from Aspen
GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. |
|
| June 17, 2013 |
| 12:20 EDT |  | SRPT | Options with increasing implied volatility: WLT LNCO SRPT LINE
Subscribe for More Information |
|
| June 14, 2013 |
| 11:23 EDT | | SRPT | Options with increasing implied volatility: TWO SRPT LNCO LINE DVA
|
|
| 06:15 EDT |  | SRPT | Leerink remains cautious on accelerated approval for Sarepta
Subscribe for More Information |
|
| June 12, 2013 |
| 19:54 EDT | | GSK | GlaxoSmithKline investigates bribe claims in China, WSJ says
Subscribe for More Information |
|
| 07:16 EDT | | GSK | GlaxoSmithKline fires head of R&D in China, WSJ says
GlaxoSmithKline has fired it's head of R&D in China after finding that he had incorporated "misinterpreted" data in a paper he helped write for a journal, Nature Medicine, according to The Wall Street Journal, citing the company. Reference Link |
|
| June 6, 2013 |
| 15:59 EDT | | GSK | FDA votes for modified restrictions on GSK's Avandia, Reuters says
Subscribe for More Information |
|
| 15:42 EDT | | GSK | FDA panel revote reaffirms modified restrictions for GSK's Avandia, Reuters says
|
| |
| 15:26 EDT | | GSK | FDA advisers say Glaxo Avandia vote may have been inaccurate, Bloomberg says
Advisers plan to take a break to assess problem with vote tally and plan to re-vote on GSK's Avandia after break, Bloomberg says. |
|
| 15:20 EDT | | GSK | FDA panel votes to modify market restrictions for Avandia, Reuters says
Subscribe for More Information |
|
| June 5, 2013 |
| 13:29 EDT | | SRPT | Options with decreasing implied volatility: INFI SRPT GES SUPN CPRT
Subscribe for More Information |
|
| 07:45 EDT |  | GSK | FDA to host a joint committee meeting
Joint Meeting of the Endocrinilogic & Metabolic Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee where the discussion on both days will be on GlaxoSmithKline's New Drug Application (NDA) 21071 for AVANDIA (Rosiglitazone Maleate) tablets is being held in FDA Offices in Silver Spring, Maryland on June 5-6 beginning at 8 am. Webcast Link |
|
| June 4, 2013 |
| 07:06 EDT | | GSK | Response Genetics achieves milestone payments totaling $1M from GlaxoSmithKline
Subscribe for More Information |
|
|
|
|
|
